A7061958
Dabrafenibmesylate , 10mMinDMSO , 1195768-06-9
CAS NO.：1195768-06-9
Empirical Formula: C24H24F3N5O5S3
Molecular Weight: 615.668
MDL number: MFCD20922872
EINECS: 689-167-4
| Pack Size | Price | Stock | Quantity |
| 1ml | RMB559.20 | In Stock |
|
| others | Enquire |
Update time: 2022-07-08
PRODUCT Properties
| Melting point: | >234oC (dec.) |
| storage temp. | Hygroscopic, -20°C Freezer, Under inert atmosphere |
| solubility | DMSO (Slightly, Heated), Methanol (Slightly) |
| form | White solid. |
| color | White to Off-White |
| Stability: | Hygroscopic |
| InChIKey | YKGMKSIHIVVYKY-UHFFFAOYSA-N |
| SMILES | S(O)(=O)(=O)C.FC1C(=CC=CC=1C1N=C(C(C)(C)C)SC=1C1C=CN=C(N)N=1)NS(C1C(=CC=CC=1F)F)(=O)=O |
Description and Uses
Dabrafenib mesylate, sold by GlaxoSmithKline under the trade name Tafinlar, was approved by the U.S. FDA in May 2013 for the treatment of metastatic BRAF-mutant melanoma. Dabrafenib reversibly inhibits the BRAF(V600E) mutant kinase as a selective ATP-competitive inhibitor which results in tumor regression.
Dabrafenib is an inhibitor of mutated BRAF kinase and has clinical activity with a manageable safety profile in clinical trials of phase 1 and 2 in patients with BRAF(V600)-mutated metastatic melanoma.
Safety
| Symbol(GHS) |  GHS07 |
| Signal word | Warning |
| Hazard statements | H319-H335-H302+H312+H332-H315 |
| Precautionary statements | P301+P312-P302+P352-P305+P351+P338 |
| HS Code | 2935909099 |
